Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies

References

• Biran N, Jagannath S, Chari A. Risk stratification in multiple myeloma, part 1: characterization of high-risk disease. Clin Adv Hematol Oncol. 2013;11(8):489–503.
   PubMedGoogle Scholar
• Sawyer JR, Tian E, Walker BA, et al. An acquired high-risk chromosome instability phenotype in multiple myeloma: jumping 1q syndrome. Blood Cancer J. 2019;9(8):62.
   PubMedGoogle Scholar
• Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood. 2016;127(24):2955–2962.
   PubMed Web of Science ®Google Scholar
• Abdallah N, Greipp P, Kapoor P, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020;4(15):3509–3519.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Attal M, Campion L, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30(16):1949–1952.
   PubMed Web of Science ®Google Scholar
• Cremer FW, Bila J, Buck I, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer. 2005;44(2):194–203.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20(11):2034–2040.
   PubMed Web of Science ®Google Scholar
• Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108(5):1724–1732.
   PubMed Web of Science ®Google Scholar
• Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021;11(4):83.
   PubMed Web of Science ®Google Scholar
• Hanamura I. Gain/amplification of chromosome arm 1q21 in multiple myeloma. Cancers (Basel). 2021;13(2):256.
   PubMed Web of Science ®Google Scholar
• Locher M, Steurer M, Jukic E, et al. The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event. Am J Hematol. 2020;95(12):1562–1571.
   PubMed Web of Science ®Google Scholar
• Nemec P, Zemanova Z, Greslikova H, et al. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant. 2010;16(4):548–554.
   PubMed Web of Science ®Google Scholar
• Shah V, Sherborne AL, Walker BA, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2018;32(1):102–110.
   PubMed Web of Science ®Google Scholar
• An G, Li Z, Tai Y-T, et al. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin Cancer Res. 2015;21(9):2148–2156.
   PubMed Web of Science ®Google Scholar
• Berry NK, Dixon-McIver A, Scott RJ, et al. Detection of complex genomic signatures associated with risk in plasma cell disorders. Cancer Genet. 2017;218-219:1–9.
   PubMed Web of Science ®Google Scholar
• Bolli N, Genuardi E, Ziccheddu B, et al. Next-generation sequencing for clinical management of multiple myeloma: ready for prime time? Front Oncol. 2020;10:189.
   PubMed Web of Science ®Google Scholar
• Zang M, Zou D, Yu Z, et al. Detection of recurrent cytogenetic aberrations in multiple myeloma: a comparison between MLPA and iFISH. Oncotarget. 2015;6(33):34276–34287.
   PubMedGoogle Scholar
• Chiecchio L, Dagrada GP, Cabanas ED, et al. Gain of 1q21 does not predict for immediate progression in MGUS. Blood. 2009;114(22):123.
   Web of Science ®Google Scholar
• Merz M, Hielscher T, Hoffmann K, et al. Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance. Leukemia. 2018;32(12):2717–2719.
   PubMed Web of Science ®Google Scholar
• Mikulasova A, Smetana J, Wayhelova M, et al. Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance. Eur J Haematol. 2016;97(6):568–575.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Bahlis NJ, Chng WJ, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017;130(24):2610–2618.
   PubMed Web of Science ®Google Scholar
• Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology. 2005;10(Suppl 1):117–126.
   PubMedGoogle Scholar
• An G, Xu Y, Shi L, et al. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 2014;99(2):353–359.
   PubMed Web of Science ®Google Scholar
• Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911–3920.
   PubMed Web of Science ®Google Scholar
• Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940–948.
   PubMed Web of Science ®Google Scholar
• D’Agostino M, Ruggeri M, Aquino S, et al. Impact of gain and amplification of 1q in newly diagnosed multiple myeloma patients receiving carfilzomib-based treatment in the Forte trial. 62nd American Society of Hematology Virtual Scientific meeting, December 5-8, 2020 [Abstract 1331].
   Google Scholar
• Zhan F, Colla S, Wu X, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007;109(11):4995–5001.
   PubMed Web of Science ®Google Scholar
• Shi L, Wang S, Zangari M, et al. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget. 2010;1(1):22–33.
   PubMedGoogle Scholar
• Treon SP, Maimonis P, Bua D, et al. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood. 2000;96(9):3147–3153.
   PubMed Web of Science ®Google Scholar
• Inoue J, Otsuki T, Hirasawa A, et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol. 2004;165(1):71–81.
   PubMed Web of Science ®Google Scholar
• Sawyer JR, Tricot G, Lukacs JL, et al. Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q. Genes Chromosomes Cancer. 2005;42(1):95–106.
   PubMed Web of Science ®Google Scholar
• Legartova S, Krejci J, Harnicarova A, et al. Nuclear topography of the 1q21 genomic region and Mcl-1 protein levels associated with pathophysiology of multiple myeloma. Neoplasma. 2009;56(5):404–413.
   PubMed Web of Science ®Google Scholar
• Walker BA, Leone PE, Chiecchio L, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15):e56–65.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD Jr., Qu P, Usmani S, et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3. Blood. 2011;118(13):3512–3524.
   PubMed Web of Science ®Google Scholar
• Zhou W, Yang Y, Xia J, et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013;23(1):48–62.
   PubMed Web of Science ®Google Scholar
• Marchesini M, Ogoti Y, Fiorini E, et al. ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma. Cancer Cell. 2017;32(1):88–100 e6.
   PubMed Web of Science ®Google Scholar
• Wu C, Yang T, Liu Y, et al. ARNT/HIF-1beta links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma. Cancer Med. 2018;7(8):3899–3911.
   PubMed Web of Science ®Google Scholar
• Teoh PJ, Chung TH, Chng PYZ, et al. IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification. Haematologica. 2020;105(5):1391–1404.
   PubMed Web of Science ®Google Scholar
• Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17(9):543–556.
   PubMed Web of Science ®Google Scholar
• Fabris S, Ronchetti D, Agnelli L, et al. Transcriptional features of multiple myeloma patients with chromosome 1q gain. Leukemia. 2007;21(5):1113–1116.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD Jr., Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276–2284.
   PubMed Web of Science ®Google Scholar
• Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020–2028.
   PubMed Web of Science ®Google Scholar
• Sawyer JR, Tricot G, Mattox S, et al. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood. 1998;91(5):1732–1741.
   PubMed Web of Science ®Google Scholar
• Sawyer JR, Tian E, Heuck CJ, et al. Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood. 2014;123(16):2504–2512.
   PubMed Web of Science ®Google Scholar
• Fournier A, Florin A, Lefebvre C, et al. Genetics and epigenetics of 1q rearrangements in hematological malignancies. Cytogenet Genome Res. 2007;118(2–4):320–327.
   PubMed Web of Science ®Google Scholar
• Lange K, Gadzicki D, Schlegelberger B, et al. Recurrent involvement of heterochromatic regions in multiple myeloma-a multicolor FISH study. Leuk Res. 2010;34(8):1002–1006.
   PubMed Web of Science ®Google Scholar
• Sawyer JR, Tian E, Thomas E, et al. Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon. Br J Haematol. 2009;147(4):484–494.
   PubMed Web of Science ®Google Scholar
• Black JC, Manning AL, Van Rechem C, et al. KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell. 2013;154(3):541–555.
   PubMed Web of Science ®Google Scholar
• Black JC, Atabakhsh E, Kim J, et al. Hypoxia drives transient site-specific copy gain and drug-resistant gene expression. Genes Dev. 2015;29(10):1018–1031.
   PubMed Web of Science ®Google Scholar
• Xu J, Xu T, Yang Y, et al. The paradoxical prognostic role of 1q21 gain/amplification in multiple myeloma: every coin has two sides. Leuk Lymphoma. 2020;61(10):2351–2364.
   PubMed Web of Science ®Google Scholar
• Li X, Chen W, Wu Y, et al. 1q21 gain combined with high-risk factors is a heterogeneous prognostic factor in newly diagnosed multiple myeloma: a multicenter study in China. Oncologist. 2019;24(11):e1132–e1140.
   PubMed Web of Science ®Google Scholar
• Grzasko N, Hus M, Chocholska S, et al. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. Leuk Lymphoma. 2012;53(12):2500–2503.
   PubMed Web of Science ®Google Scholar
• Grzasko N, Hus M, Pluta A, et al. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematol Oncol. 2013;31(1):41–48.
   PubMed Web of Science ®Google Scholar
• Varma A, Sui D, Milton DR, et al. Outcome of multiple myeloma with chromosome 1q gain and 1p deletion after autologous hematopoietic stem cell transplantation: propensity score matched analysis. Biol Blood Marrow Transplant. 2020;26(4):665–671.
   PubMed Web of Science ®Google Scholar
• Schmidt TM, Barwick BG, Joseph N, et al. Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 2019;9(12):94.
   PubMed Web of Science ®Google Scholar
• Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159–170.
   PubMed Web of Science ®Google Scholar
• Baysal M, Demirci U, Umit E, et al. Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance. Sci Rep. 2020;10(1):5991.
   PubMed Web of Science ®Google Scholar
• Wu KL, Beverloo B, Lokhorst HM, et al. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol. 2007;136(4):615–623.
   PubMed Web of Science ®Google Scholar
• Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015;5(10):e365.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV. The multiple myelomas - current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15(7):409–421.
   PubMed Web of Science ®Google Scholar
• Weinhold N, Kirn D, Seckinger A, et al. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2016;101(3):e116–9.
   PubMed Web of Science ®Google Scholar
• Lamont EB, Yee AJ, Goldberg SL, et al. Associations between amplification (1q) and prior cancer in a real-world de novo myeloma cohort. JNCI Cancer Spectr. 2021;5(1): pkaa111
   PubMed Web of Science ®Google Scholar
• Garcia JL, Hernandez JM, Gutierrez NC, et al. Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt’s lymphoma. A cytogenetic and comparative genomic hybridization study. Leukemia. 2003;17(10):2016–2024.
   PubMed Web of Science ®Google Scholar
• Le Baccon P, Leroux D, Dascalescu C, et al. Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma. Genes Chromosomes Cancer. 2001;32(3):250–264.
   PubMed Web of Science ®Google Scholar
• Davidsson J, Andersson A, Paulsson K, et al. Tiling resolution array comparative genomic hybridization, expression and methylation analyses of dup(1q) in Burkitt lymphomas and pediatric high hyperdiploid acute lymphoblastic leukemias reveal clustered near-centromeric breakpoints and overexpression of genes in 1q22-32.3. Hum Mol Genet. 2007;16(18):2215–2225.
   PubMed Web of Science ®Google Scholar
• Kudoh K, Takano M, Koshikawa T, et al. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. Clin Cancer Res. 1999;5(9):2526–2531.
   PubMed Web of Science ®Google Scholar
• Chen L, Chan TH, Guan XY. Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma. Acta Pharmacol Sin. 2010;31(9):1165–1171.
   PubMed Web of Science ®Google Scholar
• Muthuswami M, Ramesh V, Banerjee S, et al. Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition. PLoS One. 2013;8(10):e77553.
   PubMed Web of Science ®Google Scholar
• Hing S, Lu YJ, Summersgill B, et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms’ tumors. Am J Pathol. 2001;158(2):393–398.
   PubMed Web of Science ®Google Scholar
• Lo KC, Ma C, Bundy BN, et al. Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma. Clin Cancer Res. 2007;13(23):7022–7028.
   PubMed Web of Science ®Google Scholar
• Puri L, Saba J. Getting a clue from 1q: gain of chromosome 1q in cancer. J Cancer Biol Res. 2014;2:1053.
   Google Scholar
• Segers H, van den Heuvel-Eibrink MM, Williams RD, et al. Gain of 1q is a marker of poor prognosis in Wilms’ tumors. Genes Chromosomes Cancer. 2013;52(11):1065–1074.
   PubMed Web of Science ®Google Scholar
• Araki A, Chocholous M, Gojo J, et al. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma. Acta Neuropathol Commun. 2016;4(1):88.
   PubMedGoogle Scholar
• Chang H, Qi C, Yi QL, et al. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005;105(1):358–360.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi X, Trieu Y, et al. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol. 2006;135(4):486–491.
   PubMed Web of Science ®Google Scholar
• Bock F, Lu G, Srour SA, et al. Outcome of patients with multiple myeloma and CKS1B gene amplification after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(12):2159–2164.
   PubMed Web of Science ®Google Scholar
• Shah GL, Landau H, Londono D, et al. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leuk Lymphoma. 2017;58(8):1823–1831.
   PubMed Web of Science ®Google Scholar
• Nahi H, Vatsveen TK, Lund J, et al. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21. Eur J Haematol. 2016;96(1):46–54.
   PubMed Web of Science ®Google Scholar
• Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC myeloma IX trial. Leukemia. 2012;26(2):349–355.
   PubMed Web of Science ®Google Scholar
• Croft J, Ellis S, Sherborne AL, et al. Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the myeloma XI trial. Leukemia. 2021;35(7):2043–2053.
   PubMed Web of Science ®Google Scholar
• Gay F, Mina R, Rota-Scalabrini D, et al. Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: efficacy in high-risk patients. J Clin Oncol. 2021;39(15 Suppl):8002.
   Web of Science ®Google Scholar
• Weinhold N, Salwender HJ, Cairns DA, et al. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. Haematologica. 2021. DOI:https://doi.org/10.3324/haematol.2021.278888
   Google Scholar
• Giri S, Huntington SF, Wang R, et al. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Adv. 2020;4(10):2245–2253.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–1634.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775–2784.
   PubMed Web of Science ®Google Scholar
• Ishibashi M, Morita R, Tamura H. Immune functions of signaling lymphocytic activation molecule family molecules in multiple myeloma. Cancers (Basel). 2021;13(2):279.
   Web of Science ®Google Scholar
• EMPLICITI (elotuzumab) for injection. Prescribing information. Bristol-Myers Squibb Company. 2018. Available at: https://packageinserts.bms.com/pi/pi_empliciti.pdf [Cited 2021 May 11th].
   Google Scholar
• Kumaresan PR, Lai WC, Chuang SS, et al. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol. 2002;39(1–2):1–8.
   PubMed Web of Science ®Google Scholar
• Boles KS, Stepp SE, Bennett M, et al. 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunol Rev. 2001;181(1):234–249.
   PubMedGoogle Scholar
• Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329–1337.
   PubMed Web of Science ®Google Scholar
• Pazina T, James AM, MacFarlane A, et al. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. Oncoimmunology. 2017;6(9):e1339853.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10(9):91.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379(19):1811–1822.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2021;8(1):e45–54.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–1219.
   PubMed Web of Science ®Google Scholar
• DARZALEX (daratumumab) injection for intravenous use. Prescribing information. Janssen Biotech, Inc. 2021. Available at: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf [Cited 2021 May 11th].
   Google Scholar
• Premkumar V, Pan S, Lentzsch S, et al. Use of daratumumab in high risk multiple myeloma: a meta-analysis. eJHaem. 2020;1(1):267–271.
   Google Scholar
• Giri S, Grimshaw A, Bal S, et al. Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis. JAMA Oncol. 2020;6(11):1759–1765.
   PubMed Web of Science ®Google Scholar
• Mohan M, Weinhold N, Schinke C, et al. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. Br J Haematol. 2020;189(1):67–71.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Casneuf T, van Velzen J, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016 Aug 18;128(7):959–970.
   PubMed Web of Science ®Google Scholar
• Sarclisa. Summary of product characteristics April 2021 [2021 Jul 28]. Available from: https://products.sanofi.us/Sarclisa/sarclisa.pdf
   Google Scholar
• Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014;20(17):4574–4583.
   PubMed Web of Science ®Google Scholar
• Martin TG, Corzo K, Chiron M, et al. Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab. Cells. 2019;8(12):1522.
   Web of Science ®Google Scholar
• Feng X, Zhang L, Acharya C, et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23(15):4290–4300.
   PubMed Web of Science ®Google Scholar
• Harrison SJ, Perrot A, Alegre A, et al. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol. 2021;194(1):120–131.
   PubMed Web of Science ®Google Scholar
• Garcìa JB, Eufemiese RA, Storti P, et al. Role of 1q21 in multiple myeloma: from pathogenesis to possible therapeutic targets. Cells. 2021;10(6).
   Web of Science ®Google Scholar
• Spicka I, Moreau P, Martin TG, et al. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis [Abstract 8042]. J Clin Oncol. 2021;39(15_suppl): 8042.
   Web of Science ®Google Scholar
• Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361–2371.
   PubMed Web of Science ®Google Scholar
• Ogiya D, Liu J, Ohguchi H, et al. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood. 2020;136(20):2334–2345.
   PubMed Web of Science ®Google Scholar
• Krejcik J, Frerichs KA, Nijhof IS, et al. Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab. Clin Cancer Res. 2017;23(24):7498–7511.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Facon T, Bensinger WI, et al. Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2021;11(3):55.
   PubMed Web of Science ®Google Scholar
• Qu X, Chen L, Qiu H, et al. Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance. Biomed Res Int. 2015;2015:787809.
   PubMed Web of Science ®Google Scholar
• Biran N, Malhotra J, Bagiella E, et al. Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens. Am J Hematol. 2014;89(6):616–620.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–567.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar
• Lancman G, Tremblay D, Barley K, et al. The effect of novel therapies in high-molecular-risk multiple myeloma. Clin Adv Hematol Oncol. 2017;15(11):870–879.
   PubMed Web of Science ®Google Scholar
• Perrot A, Lauwers-Cances V, Tournay E, et al. Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol. 2019;37(19):1657–1665.
   PubMed Web of Science ®Google Scholar
• Spanoudakis E, Hu M, Naresh K, et al. Regulation of multiple myeloma survival and progression by CD1d. Blood. 2009;113(11):2498–2507.
   PubMed Web of Science ®Google Scholar
• Ziccheddu B, Biancon G, Bagnoli F, et al. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Adv. 2020;4(5):830–844.
   PubMed Web of Science ®Google Scholar
• Slomp A, Moesbergen LM, Gong JN, et al. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Blood Adv. 2019;3(24):4202–4214.
   PubMed Web of Science ®Google Scholar
• Wuilleme-Toumi S, Robillard N, Gomez P, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005;19(7):1248–1252.
   PubMed Web of Science ®Google Scholar
• Bolomsky A, Vogler M, Kose MC, et al. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. J Hematol Oncol. 2020;13(1):173.
   PubMed Web of Science ®Google Scholar
• Teoh PJ, An O, Chung TH, et al. Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. Blood. 2018;132(12):1304–1317.
   PubMed Web of Science ®Google Scholar
• Lazzari E, Mondala PK, Santos ND, et al. Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Nat Commun. 2017;8(1):1922.
   PubMedGoogle Scholar
• Li J, Stagg NJ, Johnston J, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing. Cancer Cell. 2017;31(3):383–395.
   PubMed Web of Science ®Google Scholar
• Bruno B, Wasch R, Engelhardt M, et al. European myeloma network perspective on CAR T-cell therapies for multiple myeloma. Haematologica. 2021;106(8):2054–2065.
   PubMed Web of Science ®Google Scholar
• Papoutselis M, Spanoudakis E. Navigating the role of CD1d/invariant natural killer T-cell/glycolipid immune axis in multiple myeloma evolution: therapeutic implications. Clin Lymphoma Myeloma Leuk. 2020;20(6):358–365.
   PubMed Web of Science ®Google Scholar
• Sherbenou DW, Aftab BT, Su Y, et al. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016;126(12):4640–4653.
   PubMed Web of Science ®Google Scholar